Unknown

Dataset Information

0

Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events.


ABSTRACT: Sustained virologic response (SVR) by interferon and interferon-free treatment can results in the reduction of advanced liver fibrosis and the occurrence of hepatocellular carcinoma in patients infected with hepatitis C virus (HCV). Recent interferon-free treatment for HCV shortens the duration of treatment and leads to higher SVR rates, without any serious adverse events. However, it is important to retreat patients who have had treatment-failure with HCV non-structural protein 5A (NS5A) inhibitor-including regimens. Combination of sofosbuvir and ledipasvir only leads to approximately 100% SVR rates in HCV genotype (GT1b), NS5A inhibitor-naïve patients in Japan. This combination is not an indication for severe renal disease or heart disease, and these patients should be treated or retreated with a different regimen.Retreatment with HCV non-structural protein 3/4A inhibitor, grazoprevir, and HCV NS5A inhibitor, elbasvir, successfully eradicated HCV RNA in three patients with HCV genotype 1b infection who discontinued prior interferon-free treatments including HCV NS5A inhibitors due to adverse events within 2 weeks.Retreatment with the 12-week combination regimen of grazoprevir and elbasvir is effective for HCV GT1b patients who discontinue the HCV NS5A inhibitor-including regimens within 2 weeks. The treatment response may be related to the short duration of initial treatment, which did not produce treatment-emergent RASs.

SUBMITTER: Kanda T 

PROVIDER: S-EPMC5882333 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Successful retreatment with grazoprevir and elbasvir for patients infected with hepatitis C virus genotype 1b, who discontinued prior treatment with NS5A inhibitor-including regimens due to adverse events.

Kanda Tatsuo T   Yasui Shin S   Nakamura Masato M   Nakamoto Shingo S   Takahashi Koji K   Wu Shuang S   Sasaki Reina R   Haga Yuki Y   Ogasawara Sadahisa S   Saito Tomoko T   Kobayashi Kazufumi K   Kiyono Soichiro S   Ooka Yoshihiko Y   Suzuki Eiichiro E   Chiba Tetsuhiro T   Maruyama Hitoshi H   Moriyama Mitsuhiko M   Kato Naoya N  

Oncotarget 20180323 22


<h4>Background</h4>Sustained virologic response (SVR) by interferon and interferon-free treatment can results in the reduction of advanced liver fibrosis and the occurrence of hepatocellular carcinoma in patients infected with hepatitis C virus (HCV). Recent interferon-free treatment for HCV shortens the duration of treatment and leads to higher SVR rates, without any serious adverse events. However, it is important to retreat patients who have had treatment-failure with HCV non-structural prote  ...[more]

Similar Datasets

| S-EPMC5030880 | biostudies-other
| S-EPMC7280513 | biostudies-literature
| S-EPMC5797068 | biostudies-literature
| S-EPMC8846299 | biostudies-literature
| S-EPMC4604396 | biostudies-literature
| S-EPMC5487656 | biostudies-literature
| S-EPMC9274559 | biostudies-literature
| S-EPMC6680317 | biostudies-literature
| S-EPMC4929798 | biostudies-literature
| S-EPMC6294167 | biostudies-literature